Life Sciences BC News, June 13, 2024 | |
|
Many thanks to our awards adjudication committee for the time and thought towards determining this year’s LSBC awards winners. Stay tuned for the awards announcement! As there is much to celebrate and BC continues to lead in life sciences, we look forward to this year's Awards Gala, presented by Farris on September 10 at the Vancouver Convention Centre West. Get your tickets while early bird pricing is still available here.
Revisit last year’s Awards Gala with the photos below.
| In other things to celebrate this week, Kardium announces $104M in new financing through a private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners. The new financing will allow Kardium to complete its PULSAR clinical study to obtain regulatory approvals, grow manufacturing capacity, and build a clinical support and commercial team in preparation for commercial launch. Read more. | As investment is a key component for company growth, we are reminded there are only two more weeks to apply to pitch at LSBC’s Invest in BC event presented by Lumira. Applications are open until June 28, 2024. This year, the event is upgraded as attendees will enjoy a two-day conference with pitches, presentations, and panels. Attendees will also have access to investors through the introduction of BIO One-on-One Partnering™ software, the first time this has been available in Canada. Entrepreneurs participating gain an invaluable platform to share their stories, receive actionable feedback, and establish connections. Learn more and apply here. |  | Another opportunity LSBC offers to prepare for an investment audience is through our Investor Readiness Program. The unique value of this program is that it draws upon the expertise and acumen of experienced life science professionals to help prepare companies to reach this important financial milestone. Applications for this program are open until July 31, 2024. Learn more and apply here. | |
|
Zymeworks announces China NMPA acceptance of Biologics License Application for zanidatamab for second-line treatment of biliary tract cancer. Under the terms of Zymeworks’ agreement with BeiGene, Zymeworks is entitled to receive an $8M milestone payment. Zymeworks also remains eligible to receive up to $164M based on additional milestones plus royalties on product sales in the Asia Pacific region. Read more.
AbbVie announces positive topline results from Phase 2 trial evaluating mirvetuximab soravtansine for treatment of ovarian cancer. Read more.
UBC Medicine researchers are among eleven UBC principal investigators receiving a combined total of $2.8M through the New Frontiers in Research Fund. This year, $33M was awarded through the fund, which supports projects reaching beyond traditional research approaches. Read more.
Qu Biologics and Foundation Medicine partner to impact care of patients with late-stage colorectal cancer. Patients will be enrolled in a Phase 2 study to assess Qu’s first-in-class treatment and leverage Foundation Medicine’s comprehensive genomic profiling. Read more.
Simon Fraser University (SFU) research group receives major funding of $14.6M to support public confidence in and access to vaccines to prepare for future pandemics. Read more.
Kapoose Creek Bio announces the identification and advancement of two lead compounds with exciting indications in neurology. Kapoose Creek Bio leverages AI for drug discovery and these compounds validate its technology platform. Read more.
| |
|
The Government of Canada invests in national coordination and Indigenous-led research on effective substance use interventions. An investment of $6 million through the Canadian Institutes of Health Research (CIHR) and the Canadian Drugs and Substances Strategy (CDSS) was announced. Read more.
Web Summit succeeds Collision and comes to Vancouver. The first Web Summit in North America will take place in Vancouver, Canada in May 2025 and bring together thousands of international entrepreneurs with the brightest minds in tech, unicorn founders, Midas investors and global media. Read more.
| |
|
HEALWELL AI Inc.'s mission is to improve healthcare and save lives through early identification and detection of disease. Learn more.
AI Clinical Research is the new approach for an independent full-service company in the area of clinical research based on cutting-edge technology. Learn more.
| |
|
Simon Fraser University (SFU) was recognized as Canada’s top university for innovation, and ranked second for industrial application, in the World University Rankings for Innovation 2024. This marks the fourth year in a row that SFU was named the top school in innovation. Read more.
Stem Cell Network (SCN) announced the recipients of their 2024 Summer Studentships. Thanks to generous funding from SCN, 20 Canadian undergraduate students will have the opportunity to undertake research with guidance from world-class regenerative medicine researchers. Read more.
Congratulations to the winners of the 2024 Novartis Oncology Young Canadian Investigator Awards. These annual awards recognize ten Canadian oncology researchers who demonstrate excellence in their field of study. Read more.
Kudos to Canary Medical, EMD Serono, IQVIA Biotech, Johnson & Johnson Innovative Medicine, KPMG, and Novartis, who were among the companies selected as finalists for the 2024 OnConferences Icon Awards in the Data and Analytics Team category! Submit your vote for a deserving finalist before July 5, 2024. Read more.
| |
|
Congratulations to Lindsay Frehlick, who will be starting a new role as the Director of Research Services at Vancouver Island University. Lindsay formerly worked as Associate Director of Research Partnerships at the University of Victoria. Read more.
Miranda Lam, Chief Legal Officer and Vice President of Business Development at Acuitas Therapeutics has been named as the BC Cancer Foundation’s new Board Chair. Miranda has been a member of the BC Cancer Foundation board since 2021. Read more.
| |
|
The Michael Smith Health Research BC-Mitacs industry-based program supports graduate students and postdoctoral fellows across British Columbia to gain experience working within BC’s life sciences sector. Receive up to $90,000 or $129,000 per 24-month term. Submit letters of intent before December 1, 2024. Learn more.
Brain Canada Foundation and CQDM are collaborating to support interprovincial biopharmaceutical projects developing solutions for the prevention, diagnosis, and treatment of brain disorders. Apply by August 15, 2024. Learn more.
Canadian SMEs are invited to apply to the Multinational Corporate Collaboration Program, an initiative from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The program provides funding and advisory services to SMEs looking to collaborate on research and development projects with multinational corporations. Register by July 5, 2024. Learn more.
Applications are open for the Fall CELS Valley Ready Accelerator. Life sciences companies looking to commercialize or raise capital in the US are invited to apply. The program begins on September 20, 2024, and applications are accepted on a rolling basis until spots are filled. Learn more.
Senior life sciences executives may now apply to Cohort VII of the adMare Academy Executive Institute. The institute is working to address Canada’s talent shortage by equipping senior biotech leaders with the skills necessary for sector growth and innovation. Applications are due by July 22, 2024. Learn more.
| |
Join International Delegations | |
|
Join the Canadian delegation to Medical Fair Asia 2024! Canadian life sciences companies interested in expanding into the Singapore/Asia market are invited to register by email before July 12, 2024. Learn more.
Global Affairs Canada invites Canadian SMEs to apply for the Canadian Biopharmaceuticals research and development partnering delegation to Germany. The delegation will travel to Germany to foster partnerships between Canadian and German SMEs, research institutions, and large corporations for collaboration in biopharmaceutical research and development. Submit your applications by June 14, 2024. Learn more.
| See our expanded list of current life sciences opportunities on our website. | |
|
At Incisive Genetics (IG), we are focused on developing our innovative lipid nanoparticle (LNP) delivery platform for genetic therapies. We believe our proprietary platform provides a solution to the most critical challenge to effective CRISPR-based gene therapy - the effective and safe delivery of active gene editing machinery into in vivo target tissues.
We have secured the exclusive worldwide license from the University of British Columbia to the foundational technology and continue to build out our intellectual property and patent portfolio through additional research and development. We have achieved significant proof of concept data for effective in vivo gene editing and have approached our studies in a systematic way that enables us to iterate on our foundational system. We are actively using our platform to develop strategies for multiple disease indications, as well as creating new genome editing modalities.
The IG team is proud to be an emerging member of the exciting British Columbia biotechnology community and appreciates the support and encouragement from Life Sciences BC. Learn more.
| |
|
Until next week!
LSBC Team
| |
|
June 18 - Join us for our Blakes Breakfast Speaking Series: Tips, Traps & Trends in Company Formation, on Tuesday, June 18 from 8:00 AM until 9:30 AM PT.
Demystify the process of company creation, understand the importance of IP, and learn about some of the tips and potential pitfalls from a legal perspective.
| |
|
September 10 - Join us on September 10, 2024, as we celebrate excellence in life sciences at the 26th Annual Life Sciences BC Awards, presented by Farris.
This distinguished occasion brings together British Columbia’s vibrant life sciences community to celebrate the outstanding achievements of our peers and recognize the tireless efforts of those who have devoted their careers to advancing health innovations.
| | |
|
|
IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites
IQVIA announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting...Read more.
| | |
|
|
IQVIA Institute: Innovative Therapies and Strong Pipeline to Combat Rise in Cancer Diagnoses
As cancer incidence continues to rise, it’s being met by wider use of innovative therapies and a robust pipeline of new drugs, according to a new report from the IQVIA Institute for Human Data Science titled, “Global Oncology Trends 2024: Outlook to 2028"…Read more.
| | |
|
|
Getinge Receives U.S. FDA 510(k) Clearance for Talis +ACG Clinical Decision Support Software, Pioneering Quality of High-acuity Care in US and EU
Getinge has been granted U.S. FDA 510(k) clearance for its innovative clinical decision support software Talis +ACG, steering in a new era of improving quality of care through promoting compliance with care protocols directly at the bedside in high acuity care environments...Read more.
| | |
|
|
UBC Researchers Receive $3.4M to Address Brain Injuries in Survivors of Intimate Partner Violence
Researchers from the University of British Columbia have been awarded $3.4 million to lead a community-based project aimed at improving the diagnosis of brain injury in survivors of intimate partner violence and exploring possible connections to Alzheimer’s disease and related dementias...Read more.
| | |
|
|
Three UBC Medicine Researchers Awarded Funding Through New Frontiers in Research Fund
Three UBC Medicine researchers are leading projects recently awarded funding through the Government of Canada’s New Frontiers in Research Fund. Dr. Nadia Fairbairn, Dr. Joerg Gsponer and Dr. Calvin Kuo are among eleven UBC principal investigators receiving a combined total of $2.8 million through the NFRF’s Exploration stream...Read more.
| | |
|
|
Stem Cell Network Announces Awardees of the 2024 Summer Studentships
The Stem Cell Network is pleased to announce the recipients of the 2024 Summer Studentships – 20 senior undergraduate students from across Canada who will spend the summer months undertaking research at Canadian academic institutions under the supervision of world-class regenerative medicine researchers...Read more.
| | |
|
|
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) Returns for its 21st year at ASCO 2024
Novartis Canada is pleased to announce the winners of the 2024 Novartis Oncology Young Canadian Investigator Awards, an annual national competition dedicated to advancing oncology through the promotion of research by supporting Canadian oncology researchers…Read more.
| | |
|
|
adMare Academy Opens Applications for Cohort VII of its Executive Institute
The adMare Academy is pleased to open applications for Cohort VII of its Executive Institute and invites senior executives working in life sciences companies across Canada to apply. The Executive Institute is at the forefront of addressing Canada’s talent shortage by empowering established and emerging biotech leaders with critical skills…Read more.
| | |
|
|
Kardium Announces $104M in New Financing for Innovative Atrial Fibrillation Treatment
Kardium raised US $104 million in a new financing round. The round is led by existing investor Fidelity Management & Research Company, together with follow-on participation by funds and accounts advised by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management…Read more.
| | |
|
|
Filament Health Announces Warrant Exercise And Note Conversion By Negev Capital And Concurrent Private Placement Of Common Shares To Benjamin Lightburn Chief Executive Officer
Filament Health announced that it has entered into agreements with Negev Capital Fund One, LP, a leading psychedelic drug development venture fund and existing investor in the Company, and Benjamin Lightburn, the Chief Executive Officer and Co-Founder of the Company, to complete a C$1.0 million bridge financing…Read more.
| | |
|
|
Zymeworks Announces China NMPA Acceptance Of Biologics License Application For Zanidatamab For Second-Line Treatment Of Biliary Tract Cancer
Zymeworks announced that the Center for Drug Evaluation of the National Medical Products Administration in China has accepted the BLA for zanidatamab for second-line treatment of HER2-positive BTC…Read more.
| | |
|
|
Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
Qu Biologics is pleased to announce that the RESILIENCE Study, a clinical trial evaluating a new immunomodulator designed to strengthen natural immunity among seniors aged 65 or older, is enrolling participants...Read more.
| | |
|
|
SFU Named Canada’s Top University for Innovation in Global WURI Rankings
Simon Fraser University is Canada’s top university for innovation and second for industrial application according to the World University Rankings for Innovation 2024 rankings. This marks the fourth consecutive year that SFU is Canada’s top university in the overall innovation category…Read more.
| | |
|
|
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
AbbVie announced positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine monotherapy in heavily pre-treated patients with ovarian cancer…Read more.
| | |
|
|
Shipper/Receiver
The Shipper/Receiver performs a variety of shipping and receiving responsibilities. The main duties include the administrative and physical tasks involved in receiving and distributing incoming goods throughout the facility as well as shipping out various types of materials...Learn more
| | |
|
|
Clinical Trial Associate 1
The Clinical Trial Associate 1 will be an individual responsible for supporting Clinical Operations team members with project-specific support related to the conduct of clinical trials activities. The Clinical Trial Associate 1 will assist the clinical research teams in ensuring the most effective and efficient conduct of clinical research studies...Learn more
| | |
|
|
Research Associate II / Senior Research Associate – Antibody Generation
This role is a permanent, on-site opportunity located in Vancouver, British Columbia. As an accomplished scientist you’ll be a key member of a highly motivated team passionate about making an impact on human health. Your role will involve multiple responsibilities critical for the successful execution of new therapeutic programs...Learn more
| | |
|
|
Events Specialist (Co-op)
Life Sciences BC is looking for an enthusiastic new co-op student to assist with preparations and execution of both in-person and virtual events. With several scheduled events happening between September and December, this role will offer a varied mix of tasks and projects and will provide fantastic experience for the chosen candidate to see how a professional industry association operates. This position will report to the Manager, Events...Learn more
| | |
|
|
Scientist/Sr. Scientist Experimental Immunology
This is a wet-lab focused position that involves the design and implementation of a new immunology-focused research program. The ideal candidate will have a deep foundational understanding of immunology with a background in immune ontogeny, virology, or vaccinology preferred...Learn more
| | |
|
|
Manager, Lab Operations
The Manager, Lab Operations will be responsible for managing the lab operations team, working with individuals and leadership in R&D to understand laboratory needs, securing and maintaining required Material Transfer Agreements, licenses and permits...Learn more
| | |
|
|
Scientist, Immunology- BC Cancer Research- Vancouver
The BC Cancer Research Institute is seeking a Research Scientist at the Assistant or Associate Professor level, to develop an independent research program in the general areas of basic and translational immunology, immunotherapy and cancer biology...Learn more
| | |
|
|
Associate Director, Immunology
The responsibilities of the Associate Director, Immunology include working with a team of researchers to develop a sustainable pipeline in immunology, supporting the attainment of departmental goals, and more...Learn more
| | |
|
|
Associate Scientist, In Vitro Biology
Zymeworks is seeking an Associate Scientist to join the In Vitro Biology group within the ADC Therapeutic Development department. The In Vitro Biology group is responsible for the in vitro functional characterization and advancement of Antibody Drug Conjugate therapeutic candidates...Learn more
| | |
|
|
Scientist, Cancer Biology, BC Cancer Research- Vancouver
The BC Cancer Research Institute is seeking an outstanding candidate for a full-time position at the rank of Scientist at the BCCRI. The BCCRI is a research institute of the University of British Columbia and the Provincial Health Services Authority...Learn more
| | |
|
|
Scientist, Proteomics -BC Cancer Research -Vancouver
The BC Cancer Research Institute is seeking a Research Scientist at the Assistant Professor level, to develop an independent research program in the general areas of biological mass spectrometry and proteomics for biomarker and target identification, or protein function analysis in cancer...Learn more
| | |
|
Post a Job on the LSBC Website | |
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARN a free repost on BioTalent Canada's The Petri Dish. After your first five posts, you will also receive 25 per cent off all job postings on The Petri Dish. Want more info? Contact talent@lifesciencesbc.ca.
| |
|
Optigo Biotherapeutics is an innovative pre-clinical stage biotherapeutics company working to develop cutting-edge treatments to address vision loss from chronic ophthalmic diseases, many of which are currently treated by monthly or bimonthly injections of drugs into the eye(s) by a retina specialist.
We believe that by reducing the frequency at which each dose of drug is delivered, we will reduce the inconvenience, discomfort, risk and expense of existing treatments. In doing so, we hope to reduce the number of patients dropping out of their treatment cycles or having to skip doses due to inconvenient timing.
Optigo Bio's pipeline therapy for retinal neovascular diseases and platform technology to enhance durability of approved and future drugs to treat Geographic Atrophy aim to prevent vision loss from these blinding retinal diseases with far fewer injections into the eye.
Learn more.
| |
If you haven't already, sign-up for this and our weekly events newsletter | |
Follow LSBC on Social Media | | | | |
